Skip to main content

Dr. Vincent Lam, M.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
135

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Medical school: University of California, San Francisco School of Medicine
  • 2010Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MD license D75865

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
135
Services billed
396
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes17385
New patient office or other outpatient visit, 60-74 minutes2727

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Tagrisso (osimertinib mesylate)29
Prochlorperazine Maleate
Other prescribers in Baltimore, MD
27
Alecensa (alectinib hcl)14
Ondansetron Hcl
Other prescribers in Baltimore, MD
14
Lumakras (sotorasib)13
Dexamethasone
Other prescribers in Baltimore, MD
12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 18 payments worth $8,656 in total to this clinician.

By type
Consulting Fee$4,400
Compensation for services other than consulting (speaking, faculty)$1,500
Travel and Lodging$1,453
Education$850
Food and Beverage$454

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 26, 2025Eli Lilly and Company
Feb 26, 2025
Consulting Fee$2,800
Feb 26, 2025Eli Lilly and Company
Feb 26, 2025
Consulting Fee$1,600
Jun 11, 2025Roche Molecular Systems, Inc.
Jun 11, 2025
Compensation for services other than consulting (speaking, faculty)$1,500
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Education
in-kind
$850
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$445
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$375
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$212
Mar 31, 2025Roche Molecular Systems, Inc.
Mar 31, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$212
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$62.61
Apr 3, 2025Roche Molecular Systems, Inc.
Apr 3, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$57.84
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Jun 25, 2025Pfizer Inc.
Jun 25, 2025
Travel and Lodging
LORBRENA · ONCOLOGY · travel to CHICAGO, IL · in-kind
$34.46
Jun 11, 2025Roche Molecular Systems, Inc.
Jun 11, 2025
Compensation for services other than consulting (speaking, faculty)$1,500
Jun 11, 2025Roche Molecular Systems, Inc.
Jun 11, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$54.00
Apr 3, 2025Roche Molecular Systems, Inc.
Apr 3, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$57.84
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Education
in-kind
$850
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$445
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$375
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$212
Apr 1, 2025Roche Molecular Systems, Inc.
Apr 1, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$62.61
Mar 31, 2025Roche Molecular Systems, Inc.
Mar 31, 2025
Travel and Lodging
travel to Tucson, AZ · in-kind
$212
Feb 26, 2025Eli Lilly and Company
Feb 26, 2025
Consulting Fee$2,800
Feb 26, 2025Eli Lilly and Company
Feb 26, 2025
Consulting Fee$1,600

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Maryland →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $428,531 in research payments for these studies, mostly to the institutions running them.

  • Neopeptide vaccine to forestall acquired resistance in advanced ALK+ non-small cell lung cancer
    Gilead Sciences, Inc.
  • A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Daiichi Sankyo Inc. · Recruiting · NCT06172478
  • An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
    Novartis Pharmaceuticals Corporation
  • A Phase 1b2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan T-DXd Monotherapy …
    AstraZeneca Pharmaceuticals LP
  • BNT116-01
    BioNTech SE
  • A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastati…
    Merck Sharp & Dohme LLC
  • BNT116
    BioNTech SE
  • A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib E7080,MK-7902 plus Pembrolizumab MK-3475 plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participant…
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Baltimore

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 20, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1265758601. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.